The Experts below are selected from a list of 489 Experts worldwide ranked by ideXlab platform
R. W. Mccallum - One of the best experts on this subject based on the ideXlab platform.
-
erythromycin a motilin agonist and gastrointestinal Prokinetic Agent
The American Journal of Gastroenterology, 1993Co-Authors: F H Weber, R. D. Richards, R. W. MccallumAbstract:: Erythromycin, a commonly used antibiotic, has recently emerged as a potential gastrointestinal Prokinetic Agent. This follows a decade of research into the mechanism of well-recognized gastrointestinal side effects of erythromycin. Early investigations demonstrated that erythromycin increased gastrointestinal motility, and more recent studies suggest that it fortuitously binds to and stimulates the receptor for the gastrointestinal peptide motilin. From this work it appears that a new and powerful class of gastrointestinal Prokinetic Agents will evolve from erythromycin and its derivatives. The role of motilin in the genesis of the fasting and fed patterns of gastrointestinal motility is emerging through the study of these motilin agonists.
-
erythromycin a motilin agonist and gastrointestinal Prokinetic Agent
The American Journal of Gastroenterology, 1993Co-Authors: F H Weber, R. D. Richards, R. W. MccallumAbstract:: Erythromycin, a commonly used antibiotic, has recently emerged as a potential gastrointestinal Prokinetic Agent. This follows a decade of research into the mechanism of well-recognized gastrointestinal side effects of erythromycin. Early investigations demonstrated that erythromycin increased gastrointestinal motility, and more recent studies suggest that it fortuitously binds to and stimulates the receptor for the gastrointestinal peptide motilin. From this work it appears that a new and powerful class of gastrointestinal Prokinetic Agents will evolve from erythromycin and its derivatives. The role of motilin in the genesis of the fasting and fed patterns of gastrointestinal motility is emerging through the study of these motilin agonists.
F H Weber - One of the best experts on this subject based on the ideXlab platform.
-
erythromycin a motilin agonist and gastrointestinal Prokinetic Agent
The American Journal of Gastroenterology, 1993Co-Authors: F H Weber, R. D. Richards, R. W. MccallumAbstract:: Erythromycin, a commonly used antibiotic, has recently emerged as a potential gastrointestinal Prokinetic Agent. This follows a decade of research into the mechanism of well-recognized gastrointestinal side effects of erythromycin. Early investigations demonstrated that erythromycin increased gastrointestinal motility, and more recent studies suggest that it fortuitously binds to and stimulates the receptor for the gastrointestinal peptide motilin. From this work it appears that a new and powerful class of gastrointestinal Prokinetic Agents will evolve from erythromycin and its derivatives. The role of motilin in the genesis of the fasting and fed patterns of gastrointestinal motility is emerging through the study of these motilin agonists.
-
erythromycin a motilin agonist and gastrointestinal Prokinetic Agent
The American Journal of Gastroenterology, 1993Co-Authors: F H Weber, R. D. Richards, R. W. MccallumAbstract:: Erythromycin, a commonly used antibiotic, has recently emerged as a potential gastrointestinal Prokinetic Agent. This follows a decade of research into the mechanism of well-recognized gastrointestinal side effects of erythromycin. Early investigations demonstrated that erythromycin increased gastrointestinal motility, and more recent studies suggest that it fortuitously binds to and stimulates the receptor for the gastrointestinal peptide motilin. From this work it appears that a new and powerful class of gastrointestinal Prokinetic Agents will evolve from erythromycin and its derivatives. The role of motilin in the genesis of the fasting and fed patterns of gastrointestinal motility is emerging through the study of these motilin agonists.
Tae Ho Lee - One of the best experts on this subject based on the ideXlab platform.
-
effects of da 9701 a novel Prokinetic Agent on gastric accommodation in conscious dogs
Journal of Gastroenterology and Hepatology, 2012Co-Authors: Eun Ran Kim, Byunghoon Min, Sung Ok Lee, Tae Ho Lee, Miwon Son, Poonglyul RheeAbstract:Background and Aim: DA-9701, a novel Prokinetic Agent formulated with Pharbitis Semen and Corydalis Tuber, has strong Prokinetic effects, and enhances gastric compliance in conscious dogs. In this study, the effects of DA-9701 on gastric accommodation were studied in conscious dogs. Methods: Beagle dogs with an implanted gastric cannula in the stomach were used in this study. After an overnight fast, the dogs received DA-9701 orally, or served as a positive control that received sumatriptan or a negative control before ingestion of a meal. The basal and postprandial gastric volumes were monitored at a constant operating pressure using an electronic barostat. To investigate the long-lasting effects on increased postprandial gastric volume, the area under the volume versus time curve (AUC) was calculated. Results: DA-9701 significantly increased the basal gastric volume compared to the negative controls (P < 0.05); the effects were comparable to sumatriptan. DA-9701 and sumatriptan significantly increased gastric accommodation compared to the negative control (P < 0.05). In the negative control, the gastric volume reached the maximal volume 40 min after the meal, and then gradually decreased. However, with DA-9701, the increased gastric volume remained significantly elevated for 60 min postprandially (P < 0.05). DA-9701 significantly increased the value of AUC compared to the negative control; this was observed during both the early and late postprandial phases (P < 0.05). Conclusions: A novel Prokinetic Agent, DA-9701, improved gastric accommodation by increasing the postprandial gastric volume; these effects persisted for 60 min after a meal.
-
effects of corydaline from corydalis tuber on gastric motor function in an animal model
Biological & Pharmaceutical Bulletin, 2010Co-Authors: Tae Ho Lee, Miwon Son, Sun Yeou KimAbstract:The aim of this study was to evaluate the Prokinetic and gastric-relaxing effects of the isoquinoline alkaloid corydaline, which was extracted from Corydalis tubers (CT). Corydaline is a marker compound used for quality control of DA-9701, a Prokinetic Agent formulated from extracts of Pharbitidis semen and Corydalis tuber that is currently in clinical trials in Korea for the treatment of functional dyspepsia (FD). DA-9701 was previously reported to be a potential therapeutic Agent for the treatment of abnormalities in gastrointestinal motor function in FD patients; however, the therapeutic effects of corydaline on FD have yet to be demonstrated in an in vivo study. In the current study, oral administration of corydaline not only significantly accelerated gastric emptying in normal rats but also improved delayed gastric emptying to near normal levels. Furthermore, corydaline induced significant gastric relaxation, shifting the pressure-volume curve towards higher volumes compared to controls. These results suggest that corydaline promotes gastric emptying and small intestinal transit and facilitates gastric accommodation.
-
gastroProkinetic effects of da 9701 a new Prokinetic Agent formulated with pharbitis semen and corydalis tuber
Phytomedicine, 2008Co-Authors: Tae Ho Lee, Miwon Son, Jeong June Choi, Donghee Kim, Seok Choi, Kang Ro Lee, Mirim JinAbstract:To develop a therapeutic for functional dyspepsia (FD), a Prokinetic Agent, DA-9701 has been newly formulated with Pharbitis Semen and Corydalis Tuber and we evaluated the gastroProkinetic effects of DA-9701 in comparison with conventional Prokinetics. Oral administration with DA-9701 not only significantly accelerated gastric emptying in normal rats but also restored the delayed gastric emptying caused by apomorphine and cisplatin up to almost normal levels. For gastrointestinal transit, DA-9701 caused FITC-dextran to travel a significantly longer distance than the control, and in the delayed GI transit models induced by laparotomy and atopine, DA-9701 considerably increased the values of mean geometric center (MGC), while the conventional Prokinetics rarely showed significant effects. Furthermore, DA-9701 drastically increased the gastric accommodation in Beagle dogs, shifting the pressure-volume curve toward considerably higher volume compared to the control, which was comparable to that of cisapride. These results indicate that DA-9701 has potential as a safe and effective therapeutic for FD patients with abnormalities in GI motor function.
Seok Choi - One of the best experts on this subject based on the ideXlab platform.
-
induction of pacemaker currents by da 9701 a Prokinetic Agent in interstitial cells of cajal from murine small intestine
Molecules and Cells, 2009Co-Authors: Seok Choi, Jeong June Choi, Donghee Kim, Jae Yeoul Jun, Jae Woong Koh, Sang Hun Kim, Myoungyun Pyo, Sangzin Choi, Jin Pub Son, Inki LeeAbstract:The interstitial cells of Cajal (ICC) are pacemaking cells required for gastrointestinal motility. The possibility of whether DA-9701, a novel Prokinetic Agent formulated with Pharbitis Semen and Corydalis Tuber, modulates pacemaker activities in the ICC was tested using the whole cell patch clamp technique. DA-9701 produced membrane depolarization and increased tonic inward pacemaker currents in the voltage-clamp mode. The application of flufenamic acid, a non-selective cation channel blocker, but not niflumic acid, abolished the generation of pacemaker currents induced by DA-9701. Pretreatment with a Ca2+-free solution and thapsigargin, a Ca2+-ATPase inhibitor in the endoplasmic reticulum, abolished the generation of pacemaker currents. In addition, the tonic inward currents were inhibited by U-73122, an active phospholipase C inhibitor, but not by GDP-β-S, which permanently binds G-binding proteins. Furthermore, the protein kinase C inhibitors, chelerythrine and calphostin C, did not block the DA-9701-induced pacemaker currents. These results suggest that DA-9701 might affect gastrointestinal motility by the modulation of pacemaker activity in the ICC, and the activation is associated with the non-selective cationic channels via external Ca2+ influx, phospholipase C activation, and Ca2+ release from internal storage in a G protein-independent and protein kinase C-independent manner.
-
gastroProkinetic effects of da 9701 a new Prokinetic Agent formulated with pharbitis semen and corydalis tuber
Phytomedicine, 2008Co-Authors: Tae Ho Lee, Miwon Son, Jeong June Choi, Donghee Kim, Seok Choi, Kang Ro Lee, Mirim JinAbstract:To develop a therapeutic for functional dyspepsia (FD), a Prokinetic Agent, DA-9701 has been newly formulated with Pharbitis Semen and Corydalis Tuber and we evaluated the gastroProkinetic effects of DA-9701 in comparison with conventional Prokinetics. Oral administration with DA-9701 not only significantly accelerated gastric emptying in normal rats but also restored the delayed gastric emptying caused by apomorphine and cisplatin up to almost normal levels. For gastrointestinal transit, DA-9701 caused FITC-dextran to travel a significantly longer distance than the control, and in the delayed GI transit models induced by laparotomy and atopine, DA-9701 considerably increased the values of mean geometric center (MGC), while the conventional Prokinetics rarely showed significant effects. Furthermore, DA-9701 drastically increased the gastric accommodation in Beagle dogs, shifting the pressure-volume curve toward considerably higher volume compared to the control, which was comparable to that of cisapride. These results indicate that DA-9701 has potential as a safe and effective therapeutic for FD patients with abnormalities in GI motor function.
Miwon Son - One of the best experts on this subject based on the ideXlab platform.
-
effects of da 9701 a novel Prokinetic Agent on gastric accommodation in conscious dogs
Journal of Gastroenterology and Hepatology, 2012Co-Authors: Eun Ran Kim, Byunghoon Min, Sung Ok Lee, Tae Ho Lee, Miwon Son, Poonglyul RheeAbstract:Background and Aim: DA-9701, a novel Prokinetic Agent formulated with Pharbitis Semen and Corydalis Tuber, has strong Prokinetic effects, and enhances gastric compliance in conscious dogs. In this study, the effects of DA-9701 on gastric accommodation were studied in conscious dogs. Methods: Beagle dogs with an implanted gastric cannula in the stomach were used in this study. After an overnight fast, the dogs received DA-9701 orally, or served as a positive control that received sumatriptan or a negative control before ingestion of a meal. The basal and postprandial gastric volumes were monitored at a constant operating pressure using an electronic barostat. To investigate the long-lasting effects on increased postprandial gastric volume, the area under the volume versus time curve (AUC) was calculated. Results: DA-9701 significantly increased the basal gastric volume compared to the negative controls (P < 0.05); the effects were comparable to sumatriptan. DA-9701 and sumatriptan significantly increased gastric accommodation compared to the negative control (P < 0.05). In the negative control, the gastric volume reached the maximal volume 40 min after the meal, and then gradually decreased. However, with DA-9701, the increased gastric volume remained significantly elevated for 60 min postprandially (P < 0.05). DA-9701 significantly increased the value of AUC compared to the negative control; this was observed during both the early and late postprandial phases (P < 0.05). Conclusions: A novel Prokinetic Agent, DA-9701, improved gastric accommodation by increasing the postprandial gastric volume; these effects persisted for 60 min after a meal.
-
effects of corydaline from corydalis tuber on gastric motor function in an animal model
Biological & Pharmaceutical Bulletin, 2010Co-Authors: Tae Ho Lee, Miwon Son, Sun Yeou KimAbstract:The aim of this study was to evaluate the Prokinetic and gastric-relaxing effects of the isoquinoline alkaloid corydaline, which was extracted from Corydalis tubers (CT). Corydaline is a marker compound used for quality control of DA-9701, a Prokinetic Agent formulated from extracts of Pharbitidis semen and Corydalis tuber that is currently in clinical trials in Korea for the treatment of functional dyspepsia (FD). DA-9701 was previously reported to be a potential therapeutic Agent for the treatment of abnormalities in gastrointestinal motor function in FD patients; however, the therapeutic effects of corydaline on FD have yet to be demonstrated in an in vivo study. In the current study, oral administration of corydaline not only significantly accelerated gastric emptying in normal rats but also improved delayed gastric emptying to near normal levels. Furthermore, corydaline induced significant gastric relaxation, shifting the pressure-volume curve towards higher volumes compared to controls. These results suggest that corydaline promotes gastric emptying and small intestinal transit and facilitates gastric accommodation.
-
gastroProkinetic effects of da 9701 a new Prokinetic Agent formulated with pharbitis semen and corydalis tuber
Phytomedicine, 2008Co-Authors: Tae Ho Lee, Miwon Son, Jeong June Choi, Donghee Kim, Seok Choi, Kang Ro Lee, Mirim JinAbstract:To develop a therapeutic for functional dyspepsia (FD), a Prokinetic Agent, DA-9701 has been newly formulated with Pharbitis Semen and Corydalis Tuber and we evaluated the gastroProkinetic effects of DA-9701 in comparison with conventional Prokinetics. Oral administration with DA-9701 not only significantly accelerated gastric emptying in normal rats but also restored the delayed gastric emptying caused by apomorphine and cisplatin up to almost normal levels. For gastrointestinal transit, DA-9701 caused FITC-dextran to travel a significantly longer distance than the control, and in the delayed GI transit models induced by laparotomy and atopine, DA-9701 considerably increased the values of mean geometric center (MGC), while the conventional Prokinetics rarely showed significant effects. Furthermore, DA-9701 drastically increased the gastric accommodation in Beagle dogs, shifting the pressure-volume curve toward considerably higher volume compared to the control, which was comparable to that of cisapride. These results indicate that DA-9701 has potential as a safe and effective therapeutic for FD patients with abnormalities in GI motor function.
